Vascular Biogenics Ltd. operating as VBL Therapeutics

Quick facts

Phase 3 pipeline

• VB-111 + bevacizumab · Oncology
  VB-111 is a targeted therapy that works by inhibiting the expression of vascular endothelial growth factor (VEGF) mRNA, while bevacizumab is a monoclonal antibody that directly binds to VEGF.
• VB-111 + Paclitaxel · Oncology
  VB-111 is a targeted anti-vascular endothelial growth factor (VEGF) aptamer that inhibits tumor growth by blocking VEGF, while Paclitaxel is a microtubule inhibitor that disrupts cell division.

Phase 2 pipeline

• VB-111

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• Vascular Biogenics Ltd. operating as VBL Therapeutics portfolio CI brief
• Vascular Biogenics Ltd. operating as VBL Therapeutics pipeline updates RSS